Sort
51,593 grants matching “hepatitis”
Integrated approaches to close the loop in type 1 diabetes
$715,496Yogish C. Kudva · Mayo Clinic Rochester · R01 · FY2009 · DK
Mechanisms of viral proteases in coronavirus replication and pathogenesis
$715,409Susan C. Baker · Loyola University Chicago · R01 · FY2018 · AI
DETECTION AND MODELS OF TOXICANT EXPOSURE
$715,297Robert H Tukey · University Of California, San Diego · P42 · FY2019 · ES
Impact of lifting work hour restrictions on first-year resident safety, health and well-being
$715,248Laura K. Barger · Brigham And Women'S Hospital · R01 · FY2021 · OH
Impact of lifting work hour restrictions on first-year resident safety, health and well-being
$715,145Laura K. Barger · Brigham And Women'S Hospital · R01 · FY2022 · OH
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
$715,140Ryan Eugene Temel · Wake Forest University Health Sciences · R01 · FY2013 · HL
Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection
$715,124Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2020 · AI
Enhancing immune regulation in gene therapy for hemophilia
$715,056Roland W. Herzog · University Of Florida · R01 · FY2017 · HL
Core--Imaging
$715,015Melvin E Clouse · Beth Israel Deaconess Medical Center · P50 · FY2007 · HL
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
$715,008Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2023 · HL
Fructose: Substrate, Stimulus, or Both?
$714,999Jean-Marc Schwarz · Touro University Of California · R01 · FY2023 · DK
Fructose: Substrate, Stimulus, or Both?
$714,999Jean-Marc Schwarz · Touro University Of California · R01 · FY2022 · DK
Fructose: Substrate, Stimulus, or Both?
$714,999Jean-Marc Schwarz · Touro University Of California · R01 · FY2019 · DK
Fructose: Substrate, Stimulus, or Both?
$714,999Jean-Marc Schwarz · Touro University Of California · R01 · FY2020 · DK
Reducing morbidity and mortality from overdose, HIV, and hepatitis C in opioid-using persons
$714,928Ronald Scott Braithwaite · New York University School Of Medicine · R01 · FY2018 · DA
Impact of lifting work hour restrictions on first-year resident safety, health and well-being
$714,927Laura K. Barger · Brigham And Women'S Hospital · R01 · FY2020 · OH
Impact of lifting work hour restrictions on first-year resident safety, health and well-being
$714,927Laura K. Barger · Brigham And Women'S Hospital · R01 · FY2019 · OH
Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer
$714,893Anna M Wu · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
T cell Immunity and the Outcome of Acute HCV Infection
$714,861Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R01 · FY2020 · AI
Functional connectivity mechanisms of opioid abstinence
$714,852Sarah Yip · Yale University · R01 · FY2025 · DA
Brain-penetrating acetylcholinesterase reactivators for several organophosphates
$714,669Janice E. Chambers · Mississippi State University · U01 · FY2015 · NS
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
$714,622Christopher L King · Case Western Reserve University · R01 · FY2021 · AI
Plant-derived vaccines against hepatitis C Cooperative *
$714,512Charles Joel Arntzen · Arizona State University-Tempe Campus · U19 · FY2008 · AI
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
$714,440Tracey McLaughlin · Stanford University · R01 · FY2025 · DK
Validating a 3rd-generation methylation measure of accelerated aging: DunedinPoAm4x
$714,405Terrie Edith Moffitt · Duke University · R01 · FY2024 · AG